Valirx (VAL) RNS Announcements

Add to Alert list
Date Time Source Announcement
18 Dec 2018 07:00 AM
RNS
Update on VAL401 - Peer-review Acceptance
10 Dec 2018 07:00 AM
RNS
Update on VAL201 Clinical Trial
05 Nov 2018 07:00 AM
RNS
Re scientific and investor meetings
01 Nov 2018 07:15 AM
EQS
ValiRx (VAL): VAL401 Phase II trial completed
24 Oct 2018 07:00 AM
RNS
Align Research Initiates Coverage
17 Oct 2018 07:00 AM
RNS
VAL201 in concluding stages of Phase I/II trial
15 Oct 2018 12:00 PM
RNS
VAL401 results shortly to be on ClinicalTrials.gov
25 Sep 2018 07:00 AM
RNS
Half-year Report
14 Sep 2018 12:42 PM
RNS
Issue of Equity
06 Sep 2018 07:00 AM
RNS
Update on Clinical Development
24 Jul 2018 12:17 PM
RNS
Result of General Meeting
17 Jul 2018 07:00 AM
RNS
US PATENT GRANT FOR THERAPEUTIC COMPOUND, VAL301
06 Jul 2018 04:42 PM
RNS
Notice of GM
14 Jun 2018 07:00 AM
RNS
VAL401 Update
24 May 2018 09:00 AM
RNS
Price Monitoring Extension
11 May 2018 02:56 PM
RNS
Holding(s) in Company
08 May 2018 12:13 PM
RNS
Result of AGM
04 May 2018 04:40 PM
RNS
Second Price Monitoring Extn
04 May 2018 04:35 PM
RNS
Price Monitoring Extension
04 May 2018 04:01 PM
RNS
Placing and grant of warrants
26 Apr 2018 02:05 PM
RNS
Second Price Monitoring Extn
26 Apr 2018 02:00 PM
RNS
Price Monitoring Extension
25 Apr 2018 04:40 PM
RNS
Second Price Monitoring Extn
25 Apr 2018 04:35 PM
RNS
Price Monitoring Extension
25 Apr 2018 07:00 AM
RNS
EU Patent Grant for Therapeutic Compound, VAL201
20 Apr 2018 10:43 AM
EQS
ValiRx (VAL): 2017: a pivotal year
19 Apr 2018 07:00 AM
RNS
GENEICE & VAL101 Update
12 Apr 2018 07:00 AM
RNS
Notice of AGM
10 Apr 2018 07:00 AM
RNS
Final Results
20 Mar 2018 07:00 AM
RNS
US Patent Grant for Therapeutic Compound, VAL201
19 Mar 2018 07:00 AM
RNS
Holding(s) in Company
16 Mar 2018 03:01 PM
RNS
Appointment of Broker
02 Mar 2018 11:01 AM
RNS
Statement re broker
09 Feb 2018 11:57 AM
RNS
Issue of options and directors dealings
02 Feb 2018 04:26 PM
RNS
Holding(s) in Company
25 Jan 2018 12:06 PM
RNS
Holding(s) in Company
23 Jan 2018 03:30 PM
RNS
Holding(s) in Company
16 Jan 2018 07:00 AM
RNS
ValiSeek Clinical Update (VAL401)
11 Jan 2018 07:00 AM
RNS
US Patent Notice of Allowance for Compound VAL201
04 Jan 2018 02:29 PM
RNS
Holding(s) in Company
03 Jan 2018 07:00 AM
RNS
Exercise of Warrants and Issue of Equity
27 Dec 2017 12:54 PM
RNS
Final Loan Note Conversion and Issue of Equity
22 Dec 2017 07:00 AM
RNS
Issue of Equity
21 Dec 2017 09:16 AM
RNS
Result of General Meeting
20 Dec 2017 03:58 PM
RNS
Warrant Exercise
20 Dec 2017 03:03 PM
RNS
Warrant Exercise
18 Dec 2017 08:45 AM
RNS
Warrant Exercise
18 Dec 2017 07:00 AM
RNS
re: VAL201 Clinical Trials
15 Dec 2017 07:00 AM
RNS
Exercise of Warrants and Issue of Equity
12 Dec 2017 07:00 AM
RNS
ValiSeek Clinical Development Update

ValiRx PLC: A Biotech Innovator on the London Stock Exchange (LSE)

ValiRx PLC, known by its ticker symbol VAL, is a trailblazer in the biotechnology sector. Its performance on the London Stock Exchange (LSE) has been remarkable, with the ValiRx share price reflecting the company's consistent growth and success.

As a member of the LSE, ValiRx PLC aligns with the London Stock Exchange Group's (LSEG) mission of supporting innovative and growing businesses. The LSEG recognises ValiRx PLC as a significant player, contributing to the robust and diverse ecosystem of the LSE.

The ValiRx share price on the LSE not only underscores its financial stability but also its strategic vision in the biotechnology industry. ValiRx PLC's journey on the LSE is a testament to its robust business model and its ability to create value for its stakeholders.

In conclusion, ValiRx PLC's association with the LSE and LSEG symbolises its commitment to growth, innovation, and value creation. As ValiRx PLC continues to thrive on the LSE, it sets the bar high for the biotechnology industry, contributing to the dynamic and diverse ecosystem of the LSEG. With its focus on cancer therapeutics, ValiRx is a key player in the healthcare sector, making strides in medical research and development.

UK 100

Latest directors dealings